Will you have Complex regional pain syndrome with Copaxone - from FDA reports


Complex regional pain syndrome is reported only by a few people who take Copaxone. We study 41,238 people who have side effects while taking Copaxone from FDA. Among them, 3 have Complex regional pain syndrome. Find out below who they are, when they have Complex regional pain syndrome and more.

What's eHealthMe?

eHealthMe is a health data analysis company based in Mountain View, California. eHealthMe monitors and analyzes the outcomes of drugs and supplements that are currently on the market. The results are readily available to health care professionals and consumers.

eHealthMe has released original studies on market drugs and worked with leading universities and institutions such as IBM, London Health Science Centre, Mayo Clinic, Northwestern University and VA. eHealthMe studies have now been referenced in over 500 peer-reviewed medical publications.

How we gather our data?

Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference.

The information that eHealthMe collects includes:

  • Side effects (including severity and how people recover from them)
  • Associated conditions or symptoms
  • Drug effectiveness
  • Demographic data regarding drug use

How the study uses the data?

The study is based on glatiramer acetate (the active ingredients of Copaxone) and Copaxone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Synonyms of Complex regional pain syndrome are also considered in the study.

What is Copaxone?

Copaxone has active ingredients of glatiramer acetate. It is often used in multiple sclerosis. (latest outcomes from Copaxone 41,766 users)

What is Complex regional pain syndrome?

Complex regional pain syndrome (long lasting pain condition most often affecting one of the limbs (arms, legs, hands, or feet)) has been reported by people with pain, osteoporosis, complex regional pain syndrome, depression, rheumatoid arthritis (latest reports from 3,913 Complex regional pain syndrome patients).

How to use the study?

Patients can bring a copy of the report to their healthcare provider to ensure that all drug risks and benefits are fully discussed and understood. It is recommended that patients use the information presented as a part of a broader decision-making process.

On Mar, 14, 2019

41,238 people reported to have side effects when taking Copaxone.
Among them, 3 people (0.01%) have Complex regional pain syndrome

Number of reports submitted per year:

Could Copaxone cause Complex regional pain syndrome?

Gender of people who have Complex regional pain syndrome when taking Copaxone *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Complex regional pain syndrome when taking Copaxone *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 33.33 %
  • 40-49: 66.67 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

Top co-used drugs for these people *:

  1. Zanaflex: 2 people, 66.67%
  2. Diovan: 2 people, 66.67%
  3. Ambien Cr: 2 people, 66.67%
  4. Cymbalta: 2 people, 66.67%
  5. Cytomel: 2 people, 66.67%
  6. Mirapex: 2 people, 66.67%
  7. Marinol: 2 people, 66.67%
  8. Vytorin: 2 people, 66.67%
  9. Lasix: 2 people, 66.67%
  10. Coq10: 1 person, 33.33%

Top other side effects for these people *:

  1. Gait Disturbance: 3 people, 100.00%
  2. Fatigue (feeling of tiredness): 3 people, 100.00%
  3. Pain In Extremity: 3 people, 100.00%
  4. Fibromyalgia (a long-term condition which causes pain all over the body): 2 people, 66.67%
  5. Heart Rate Increased: 2 people, 66.67%
  6. Hyperaesthesia: 2 people, 66.67%
  7. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 66.67%
  8. Erythromelalgia (episodes of pain, redness, and swelling in various parts of the body): 2 people, 66.67%
  9. Drug Ineffective: 2 people, 66.67%
  10. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (long lasting infection of nerves outside brain and spinal cord): 2 people, 66.67%

* Approximation only. Some reports may have incomplete information.

Do you have Complex regional pain syndrome while taking Copaxone?

You are not alone:

Related publications that referenced our studies

Related studies

Drugs that are associated with Complex regional pain syndrome
Complex regional pain syndrome (713 drugs)
Could your condition cause Complex regional pain syndrome
Complex regional pain syndrome (454 conditions)
Copaxone side effects

Browse side effects by gender and age

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Copaxone
a b c d e f g h i j k l m n o p q r s t u v w x y z
Compare Copaxone with similar drugs

What would happen?

Predict new side effects and undetected conditions when you take Copaxone and have Complex regional pain syndrome

FDA reports used in this study

Recent updates

Recent general studies
Recent personal studies

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.